stockrowPrestige Consumer Healthcare Inc. (PBH) vs Xeris Biopharma Holdings, Inc. (XERS)
- Prestige Consumer Healthcare Inc. PBH 42.66 −3.75%
- Xeris Biopharma Holdings, Inc. XERS 14.16 +8.26%
Prestige Consumer Healthcare Inc. and Xeris Biopharma Holdings, Inc. are both Drug Manufacturers Specialty & Generic companies. Xeris Biopharma Holdings, Inc. is the larger, with a market value of $2.4B against $2.1B — 1.1× the size. Xeris Biopharma Holdings, Inc. has negative trailing earnings, so its P/E is not meaningful; Prestige Consumer Healthcare Inc. trades at 13.7×. Xeris Biopharma Holdings, Inc. grew revenue faster over the last twelve months: 38.4% against 5.10%. Prestige Consumer Healthcare Inc. has the higher net margin (13.3% vs −1.76%) and the lower return on invested capital (9.59% vs 27.2%). Across the 21 metrics below, Prestige Consumer Healthcare Inc. leads on 14 and Xeris Biopharma Holdings, Inc. on 7.
Valuation
Profitability
| Metric | PBH | XERS | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | 52.47% | 87.38% | 53.51% |
| Operating margin | 24.95% | 12.70% | 0.00% |
| Net margin | 13.29% | (1.76%) | (2.45%) |
| Free cash flow margin | 18.35% | 20.00% | 0.00% |
| Return on equity | 8.23% | (27.11%) | (0.80%) |
| Return on assets | 3.80% | (1.64%) | (1.67%) |
| Return on invested capital | 9.59% | 27.22% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack